HCW Biologics Inc. Revenue from Contract with Customer, Excluding Assessed Tax
HCW Biologics Inc. (HCWB) reported Revenue from Contract with Customer, Excluding Assessed Tax of $121.73 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-14
- HCW Biologics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $121.73K.
- HCW Biologics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $6.50M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month |
|---|---|---|
| 2026-06-30 | $121.73K 10-Q · filed 2026-08-14 | $6.70M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $6.50M 10-Q/A · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |